Targeted Lysophosphatidic Acid Receptor Antagonists for Hepatocellular Carcinoma Chemoprevention

HPB - United Kingdom
doi 10.1016/j.hpb.2017.02.119
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Lysophosphatidic Acid Type 2 Receptor Agonists in Targeted Drug Development Offer Broad Therapeutic Potential

Journal of Lipid Research
BiochemistryEndocrinologyCell Biology
2019English

Targeted Therapy in Hepatocellular Carcinoma

International Journal of Hepatology
Hepatology
2011English

Lysophosphatidic Acid Receptor 1 (LPAR1; EDG2; LPA1)

Science-Business eXchange
2011English

Development of Asialoglycoprotein Receptor-Targeted Nanoparticles for Selective Delivery of Gemcitabine to Hepatocellular Carcinoma

Molecules
Organic ChemistryMolecular MedicineAnalytical ChemistryTheoretical ChemistryPharmaceutical ScienceMedicineDrug DiscoveryChemistryPhysical
2019English

Molecular Targeted Therapy of Hepatocellular Carcinoma

Journal of Cancer Therapy
2013English

Neurobiology of the Edg2 Lysophosphatidic Acid Receptor.

The Japanese Journal of Pharmacology
2001English

Synergistic Combination for Chemoprevention of Hepatocellular Carcinoma: An in Silico and in Vitro Approach

Basic and Clinical Pharmacology and Toxicology
MedicineToxicologyPharmacology
2017English

Characterization of a Receptor Subtype-Selective Lysophosphatidic Acid Mimetic

Molecular Pharmacology
Molecular MedicinePharmacology
1998English

Lysophosphatidic Acid Receptor 5 Inhibits B Cell Antigen Receptor Signaling and Antibody Response

Journal of Immunology
AllergyImmunology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy